Roivant Sciences is trading at $30.03, down 24.49% after closing at $39.77 on September 18, 2026; the move may reflect an after-hours liquidity or data anomaly pending verification.
- Recent coverage was broadly positive, including Stifel’s Buy rating and $51 target; JPMorgan reiterated Overweight.
- The broader market finished higher, with no confirmed market-wide trigger or negative company-specific catalyst explaining the sharp, apparently isolated decline.